Keywords: gsk/xenoport, drug, fails, ph, ii, dpn, study

GSK/Xenoport drug fails Ph II DPN study

Article | 28 April 2009

UK drug major GlaxoSmithKline and USA-based XenoPort reported data showing that gabapentin enacarbil missed its primary endpoint in a mid-stage ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

GSK

Go to company listing

Related Drugs

gabapentin

Neurontin

Lyrica

Pregabalin

Go to drug listing